HighTide Therapeutics
Manufacturing · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11140 Rockville Pike Ste 100-551, Rockvi...Phone Number
+61 414668863Website
www.hightidetx.comRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About HighTide Therapeutics
HighTide Therapeutics, Inc. is focused on developing innovative therapeutic solutions for chronic metabolic diseases, particularly those related to cardiovascular-kidney-metabolic (CKM) conditions. Their lead candidate, HTD1801, targets diseases driven by insulin resistance and chronic inflammation. The company also has a growing discovery portfolio aimed at addressing unmet needs in this area. HighTide Therapeutics is dedicated to advancing treatments that improve patient outcomes in chronic metabolic diseases.Explore more
HighTide Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
AL
Director, Clinical Science
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HighTide Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when HighTide Therapeutics launches new products
Check if HighTide Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if HighTide Therapeutics is spiking on competitors!
HighTide Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on HighTide Therapeutics recently announced quarterly report
Click to see if HighTide Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once HighTide Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at HighTide Therapeutics
Recommended Actions
Reach out to Masked Content who joined HighTide Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to HighTide Therapeutics
Compare insights from companies similar to HighTide Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
HighTide Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HighTide Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HighTide Therapeutics.
HighTide Therapeutics financials insights
Gather financial insights about HighTide Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$60M
2023
Series C
$107M
HighTide Therapeutics Tech Stack
A closer look at the technologies used by HighTide Therapeutics
See more technologies
Most Recent Scoops
Event
Events
Funding
New Hire
Management Move
Daniel Ripley has joined the company as Senior VP, Business Development. Previously, Ripley was Head of Global Business Development for Alpha Biopharma.
New Hire
Executive Move
New Hire
Executive Move
HighTide Therapeutics News & Media
Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: Moving Beyond the "Blockbuster" Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach
HONG KONG, Apr 2, 2026 - (ACN Newswire) - Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights into a company's pipeline potential and reflecting how industry veterans gauge the sector’s future. A clear signal of the company’s growth arrived in February 2026, when HighTide Therapeutics (2511.HK) announced a high-profile executive appointment: Dr. Filip Surmont joined the company as Chief Medical Officer (CMO). ForEASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
HONG KONG, Sep 17, 2025 - (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic diseases, announced that data from the Phase 3 SYMPHONY 2 trial evaluating the safety and efficacy of HTD1801 in patients with type 2 diabetes mellitus (T2DM) is being presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna. HTD1801,HighTide Therapeutics And 2 Other Asian Penny Stocks To Watch Closely
Amidst a backdrop of fluctuating global trade policies and easing inflation, Asian markets have been navigating a complex economic landscape. For investors eyeing opportunities in smaller or newer companies, penny stocks—though an outdated term—still hold potential for growth at accessible price points. These stocks can offer notable value when backed by strong financials, making them intriguing options for those seeking hidden gems with promising long-term prospects.HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
HONG KONG, Apr 24, 2025 - (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. The presentations include post-hoc analyses of two Phase 2 clinical studies of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HighTide Therapeutics
Sign Up For FreeTo access detailed company insights
HighTide Therapeutics, Inc. is focused on developing innovative therapeutic solutions for chronic metabolic diseases, particularly those related to cardiovascular-kidney-metabolic (CKM) conditions. Their lead candidate, HTD1801, targets diseases driven by insulin resistance and chronic inflammation. The company also has a growing discovery portfoli... Read More
